Activin and Inhibin

CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma

CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma

CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC 50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancerIn VitroCRT0273750 shows high potency in both the biochemical (IC 50 = 0.01 μM) and plasma

CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 ( OC2 , a master regulator of androgen receptor) with a K d of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 hydrochloride induces

CT1812 (Sigma-2 receptor antagonist 1) is a sigma-2 (σ-2) receptor antagonist.Form:SolidIC50&amp: Target:Sigma 2 Receptor.

CT1812 (Sigma-2 receptor antagonist 1) is a sigma-2 (σ-2) receptor antagonist.Form:SolidIC50&amp: Target:Sigma 2 Receptor.

CT1812 (Sigma-2 receptor antagonist 1) is a sigma-2 (σ-2) receptor antagonist.Form:SolidIC50&amp: Target:Sigma 2 Receptor.

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances

CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9 . The IC 50 value for MMP-9 is ~8 μM.Appearance:SolidIC50&amp: Target:MMP-2 MMP-9In Vitro:CTTHWGFTLC, CYCLIC TFA inhibits endothelial and tumor cell

CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9 . The IC 50 value for MMP-9 is ~8 μM.Appearance:SolidIC50&amp: Target:MMP-2 MMP-9In Vitro:CTTHWGFTLC, CYCLIC TFA inhibits endothelial and tumor cell

CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9 . The IC 50 value for MMP-9 is ~8 μM.Appearance:SolidIC50&amp: Target:MMP-2 MMP-9In Vitro:CTTHWGFTLC, CYCLIC TFA inhibits endothelial and tumor cell